Alphatec Holdings (ATEC) Slid on Investors’ Reaction Towards Company and Sector Factors Soumya Eswaran May 14, 2026 3 min read ATEC MSTR Polen Capital, an investment management company, released its first-quarter 2025 investor letter for "Polen 5Perspectives Small Growth Strategy". A copy of the letter is available to download here. Polen 5Perspectives Small Growth Composite Portfolio returned 3.3% gross and 3.0% net of fees, respectively, in the first quarter of 2026, compared to the -2.8% return of the Russell 2000 Growth Index.
Small caps performed strongly at the start of the first quarter, but market volatility caused a shift in focus. Initially, fears of AI disruption in software dominated, followed by worries over private credit redemptions raising broader systemic risk concerns. By March, concerns shifted mainly to increasing geopolitical risks and their impact on rates and inflation.
This heightened volatility is expected to continue for the foreseeable future. The importance of adopting a flexible approach to opportunities has become clear this year. In addition, please check the Strategy's top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Polen 5Perspectives Small Growth Strategy highlighted Alphatec Holdings, Inc. (NASDAQ:ATEC). Alphatec Holdings, Inc. (NASDAQ:ATEC) is a medical technology company that specializes in developing technologies for the surgical treatment of spinal disorders. On May 13, 2026, Alphatec Holdings, Inc. (NASDAQ:ATEC) closed at $7.55 per share.
One-month return of Alphatec Holdings, Inc. (NASDAQ:ATEC) was -30.22%, and its shares lost 40.74% over the past 52 weeks. Alphatec Holdings, Inc. (NASDAQ:ATEC) has a market capitalization of $1.16 billion. Polen 5Perspectives Small Growth Strategy stated the following regarding Alphatec Holdings, Inc. (NASDAQ:ATEC) in its Q1 2026 investor letter: "Alphatec Holdings, Inc. (NASDAQ:ATEC) is a medical technology company focused on spine surgery.
The company has been gaining share through innovation, surgeon adoption, and a comprehensive procedural approach. During the quarter, shares declined as investors reacted to a combination of company-specific and broader healthcare factors. While revenue growth remains strong, profitability continues to lag expectations as the company invests heavily in salesforce expansion and new product launches.
Extract — continue reading at the source.
